

Table 6
For Harm Monitoring: Summary of COVID-19 and Severe COVID-19 Starting After First Injection
Safety Set

	Placebo (N=15165)	mRNA-1273 (N=15184)	Total (N=30350)
Number of Subjects with Positive RT-PCR at Baseline, N1 (%) [1]	95 (0.6)	87 (0.6)	182 (0.6)
Number of Subjects with Negative RT-PCR at Baseline, N2 (%) [1]	14875 (98.1)	14883 (98.0)	29759 (98.1)
COVID-19 Regardless of RT-PCR Results at Baseline			
Number of Subjects with COVID-19 Starting After First Injection, n1/N (%) [1]	175/15165 (1.2)	20/15184 (0.1)	195/30350 (0.6)
Number of Subjects with Severe COVID-19 Starting After First Injection, n1/N (%) [1]	23/15165 (0.2)	2/15184 (<0.1)	25/30350 (<0.1)
Number of Subjects with Secondary Definition of COVID-19 Starting After First Injection, n1/N (%) [1]	194/15165 (1.3)	23/15184 (0.2)	217/30350 (0.7)
COVID-19 Excluding Subjects with Positive RT-PCR at Baseline			
Number of Subjects with COVID-19 Starting After First Injection, n2/(N-N1) (%) [2]	170/15070 (1.1)	14/15097 (<0.1)	184/30168 (0.6)
Number of Subjects with Severe COVID-19 Starting After First Injection, n2/(N-N1) (%) [2]	21/15070 (0.1)	2/15097 (<0.1)	23/30168 (<0.1)
Number of Subjects with Secondary Definition of COVID-19 Starting After First Injection, n2/(N-N1) (%) [2]	188/15070 (1.2)	15/15097 (<0.1)	203/30168 (0.7)

[1] Percentages are based on the Safety Set.

[2] n2 includes subjects with negative RT-PCR at baseline, and N-N1 includes subjects with negative or missing RT-PCR at baseline.

Program: \Moderna MODMRNA1273P301_U\Harm Monitoring 1111\TLF\t06.sas 19NOV2020 20:10